New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)

Longeveron stem cell therapy Phase 2a clinical data in Alzheimer's disease selected for poster presentation at 2026 AAIC.

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.